Catalent
CTLT
#1737
Rank
$11.52 B
Marketcap
$63.48
Share price
0.00%
Change (1 day)
13.78%
Change (1 year)
Catalent is an American pharmaceutical contract research and development company.

Revenue for Catalent (CTLT)

Revenue in 2024 (TTM): $4.42 Billion USD

According to Catalent's latest financial reports the company's current revenue (TTM ) is $4.42 Billion USD. In 2023 the company made a revenue of $4.09 Billion USD a decrease over the revenue in the year 2022 that were of $4.75 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Catalent from 2013 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) $4.42 B7.91%
2023 $4.09 B-13.85%
2022 $4.75 B6.11%
2021 $4.48 B29.38%
2020 $3.46 B26.96%
2019 $2.72 B9.7%
2018 $2.48 B8.19%
2017 $2.29 B21.29%
2016 $1.89 B3.35%
2015 $1.83 B-0.66%
2014 $1.84 B2.19%
2013 $1.80 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Supernus Pharmaceuticals
SUPN
$0.68 B-84.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
$0.21 B-95.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Jazz Pharmaceuticals
JAZZ
$4.15 B-5.97%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Intercept Pharmaceuticals
ICPT
$0.31 B-92.82%๐Ÿ‡บ๐Ÿ‡ธ USA